- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Liver Disease Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Health disparities and outcomes
- Cancer Mechanisms and Therapy
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Liver Disease and Transplantation
- Nutritional Studies and Diet
- Ovarian cancer diagnosis and treatment
- Genetic Associations and Epidemiology
81th Hospital of PLA
2024
Zhongshan Hospital of Xiamen University
2022-2024
Fudan University
2022-2024
Background and Objectives: To assess the efficacy safety of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed (HAICROX) as an alternative treatment option for advanced hepatocellular carcinoma (HCC) patients who are ineligible for, or failed, transarterial chemoembolization (TACE) treatment. Materials Methods: From July 2020 to November 2021, a total 35 HCC were enrolled received HAIC raltitrexed. The overall survival (OS) time progression (TTP) primary...
The prognostic value of the tumor growth rate (TGR) in huge hepatocellular carcinoma (HHCC) patients treated with transcatheter arterial chemoembolization (TACE) as an initial treatment remains unclear. This two-center retrospective study was conducted 97 suffering from HHCC. Demographic characteristics, oncology and some serological markers were collected for analysis. TGR significantly linear associated risk death when applied to restricted cubic splines. optimal cut-off -8.6%/month,...
Background and Objectives: The recurrence outcome in patients who underwent microwave ablation (MWA) with or without transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) within Milan criteria remains unclear. aim of this retrospective study was to identify the predictive factors these patients. Materials Methods: From May 2018 April 2021, 66 HCC were enrolled. Local tumor progression (LTP) recurrence-free survival (RFS) evaluated. Univariate multivariate analyses used...